Mark Chin - Mar 31, 2022 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role: Director
Signature: /s/ Pamela Connealy, Attorney-in-Fact for Mark Chin
Stock symbol: PYXS
Transactions as of: Mar 31, 2022
Transactions value $: $0
Form type: 4
Date filed: 4/4/2022, 04:15 PM
Previous filing: Oct 15, 2021
Next filing: Apr 25, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PYXS	Common Stock	Award	$0	+66.8K		$0.00	66.8K	Mar 31, 2022	Direct	F1
holding	PYXS	Common Stock						1.75M	Mar 31, 2022	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
F2	These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

Content

Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.